ACB Aurora Cannabis Inc.

Hostile takeovers are called hostile for a reason, and this one is getting ugly.

Aurora is asking Alberta regulators to fix what it calls three deficiencies in Curaleaf’s $4 hostile bid, while Curaleaf says the complaints are technicalities and vows to keep fighting.

Aurora Cannabis gains momentum as international medical cannabis growth lifts earnings estimates, while Baidu faces pressure from weakness in its core business.

Aurora Cannabis stock has moved sharply higher from its recent lows following broad industry developments and fundamental improvements to the core business.

Key Takeaways; Psychedelic Sector Optimi Health Plans to Initiate Phase 3 Clinical Trial Evaluating MDMA Therapy for Individuals with PTSD Eli Lilly Completed $2.8 Billion Acquisition of AtaiBeckley, Expanding its Mental Health Pipeline Definium’s Phase 3 Panorama Trial Delivered Positive Results for DT120 in Generalized Anxiety Disorder Psyence BioMed Established Texas Entity to Advance U.S. […]

Curaleaf took a hostile, $4-per-share cash-and-stock tender offer for Aurora Cannabis directly to shareholders after private merger talks stalled, seeking global scale ahead of federal cannabis reforms.

Curaleaf Holdings (USOTC:CURLF) has sent a letter to Aurora Cannabis (NASDAQ:ACB) shareholders urging them to tender their shares to its outstanding acquisition offer after Aurora’s board declined to engage with the proposal. Under the offer, Aurora shareholders would receive 0.

Curaleaf is asking Alberta regulators to halt Aurora’s share sales, arguing the company shouldn’t be diluting shareholders at $3.04 while rejecting a $4 takeover offer.

Curaleaf published its second response to Aurora’s rejection of the hostile bid. The fight is spilling out into the public.

Aurora Cannabis CEO Miguel Martin called a takeover bid from cannabis company Curaleaf 'inadequate' and said that it was not in shareholder's best interest after the company's board unanimously rejected the offer. Martin said that he is not against offers on principle and would recommend going with another bid if it had the right value and structure for shareholders.

Aurora Cannabis urged its shareholders to reject an unsolicited $272 million hostile takeover bid from Curaleaf Holdings, saying the offer is inadequate and undervalues parts of its business.

Aurora Cannabis (ACB.TO) urged shareholders to reject Curaleaf Holdings (CURA.TO)'s unsolicited take

Key Takeaways; Cannabis Sector Aurora Cannabis Urged Shareholders to Reject Curaleaf’s Hostile Takeover Bid Tilray Expanded Global Cannabis Production as International Medical Demand Continues to Grow Key Takeaways; Psychedelic Sector Jupiter Neurosciences Raised $2 Million as the Company Advances its Parkinson’s Drug Program Optimi Health Secured Discretionary Equity Facility as Psychedelic Drug Business Expands SciSparc […]

Aurora's turnaround could make Curaleaf's offer look too low.

Like Logan Roy on HBO, Aurora CEO Miguel Martin is fending off a bear hug. We’ll see if a deal gets done.

In a statement on Monday, Curaleaf rejected Aurora’s assertions of inaccuracies in its unsolicited bid and accused the Canadian firm of using selective metrics to deflect from years of underperformance.

Aurora said its Board, along with a newly formed Special Committee of independent directors, is reviewing Curaleaf's proposal as it determines the future course of action.

Green Thumb Industries is in a strong position to acquire other cannabis companies, but will that happen?

After a huge gold rush, the marijuana sector stumbled, and now consolidation is gaining momentum.

The U.S. company formally kicked off the bid for its peer across the northern border.

Tilray surged Wednesday alongside Canopy Growth and Aurora Cannabis, but one number from 2026 tells a very different story about why today's rally leaves the real problem untouched.

Curaleaf (CURA.TO)on Tuesday formally launched its unsolicited takeover bid for Aurora Cannabis (ACB

Curaleaf Holdings has delivered a sharp 70.0% share price decline over the past five years, yet the stock still screens as cheap on several valuation checks. This puts recent news around expansion plans under a brighter spotlight for investors trying to judge whether today’s price is attractive. The 70.0% drop over five years suggests investors have already priced in a lot of sector and company specific challenges, so any recovery case now starts from a much lower base. Curaleaf’s push to...

Cannabis consolidation appears to be accelerating.

Curaleaf CEO Boris Jordan says he tried to play nice before taking its $4-per-share Aurora bid public. “We wanted to be friendly,” he said in an interview.

Curaleaf is attempting to acquire Canopy Growth's rival, Aurora Cannabis, and there could be more consolidation to come in the industry.

Aurora Cannabis would expand Curaleaf's international presence, but it hasn't been a strong business in recent years.